Published in Cancer Res on November 01, 1994
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
Pleiotropic role for MYCN in medulloblastoma. Genes Dev (2010) 1.84
Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol (2007) 1.50
APC mutations in sporadic medulloblastomas. Am J Pathol (2000) 1.40
Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer (2005) 1.19
The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol (1996) 1.16
Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci U S A (1999) 1.15
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med (2011) 1.12
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol (2008) 1.12
The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A (1998) 1.00
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol (2012) 0.97
p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. Genes Cancer (2011) 0.96
The rationale for targeted therapies in medulloblastoma. Neuro Oncol (2013) 0.92
Cytoplasmic p53 and activated Bax regulate p53-dependent, transcription-independent neural precursor cell apoptosis. J Histochem Cytochem (2009) 0.89
Expression of a human polyomavirus oncoprotein and tumour suppressor proteins in medulloblastomas. Mol Pathol (2001) 0.86
Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics. Expert Opin Ther Targets (2013) 0.84
Recent advances in embryonal tumours of the central nervous system. Childs Nerv Syst (2005) 0.82
HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol (2012) 0.81
WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma. Neurosurgery (2012) 0.81
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines. J Exp Clin Cancer Res (2013) 0.81
Expression of stabilized beta-catenin in differentiated neurons of transgenic mice does not result in tumor formation. BMC Cancer (2002) 0.81
Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli. Am J Pathol (2003) 0.80
The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system. Br J Cancer (2002) 0.79
Overexpression of HLA-DR is associated with prognosis of glioma patients. Int J Clin Exp Pathol (2015) 0.75
Evasion of cell senescence in SHH medulloblastoma. Cell Cycle (2016) 0.75
Cerebellum Development and Tumorigenesis: A p53-Centric Perspective. Trends Mol Med (2016) 0.75
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. J Exp Clin Cancer Res (2016) 0.75
Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms. Sarcoma (1997) 0.75
Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature (1983) 11.57
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A (1999) 7.70
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci U S A (1997) 3.48
Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour. Nature (1984) 3.37
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature (1985) 2.96
Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics (1998) 2.79
Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet (1989) 2.56
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Clonal genomic alterations in glioma malignancy stages. Cancer Res (1988) 2.39
Genetic origin of mutations predisposing to retinoblastoma. Science (1985) 2.22
Spontaneous deletion formation at the aprt locus of hamster cells: the presence of short sequence homologies and dyad symmetries at deletion termini. EMBO J (1986) 2.20
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature (1987) 2.14
Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci U S A (1989) 2.14
Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell (1990) 2.06
Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A (1997) 2.04
Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A (1990) 2.03
Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A (1996) 2.02
Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome (2001) 1.94
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A (1995) 1.91
Familial predisposition to Wilms' tumour does not map to the short arm of chromosome 11. Nature (1988) 1.84
Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res (1994) 1.84
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem (1998) 1.79
Genetics of cancer predisposition. Cancer Res (1987) 1.78
D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res (1999) 1.67
Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet (1994) 1.66
Alzheimer's disease: current knowledge, management and research. CMAJ (1997) 1.66
Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (1998) 1.59
Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci U S A (1996) 1.53
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res (2001) 1.47
Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. Proc Natl Acad Sci U S A (1987) 1.47
Structure of mutant alleles at the aprt locus of Chinese hamster ovary cells. J Mol Biol (1983) 1.45
Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem (1990) 1.43
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res (1997) 1.43
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene (2011) 1.42
Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res (1991) 1.42
Human collagen genes encoding basement membrane alpha 1 (IV) and alpha 2 (IV) chains map to the distal long arm of chromosome 13. Proc Natl Acad Sci U S A (1987) 1.41
Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res (1994) 1.39
Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res (1996) 1.38
Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res (1999) 1.37
Nucleotide sequence of hamster adenine phosphoribosyl transferase (aprt) gene. Nucleic Acids Res (1986) 1.37
DNA amplification--deletion in a spontaneous mutation of the hamster aprt locus: structure and sequence of the novel joint. Nucleic Acids Res (1986) 1.35
Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res (2001) 1.34
Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res (1992) 1.31
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
Chromosome 13 homozygosity in osteosarcoma without retinoblastoma. Am J Hum Genet (1986) 1.30
Next-nucleotide effects in mutations driven by DNA precursor pool imbalances at the aprt locus of Chinese hamster ovary cells. Proc Natl Acad Sci U S A (1987) 1.28
Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides (1995) 1.26
DNA sequence analysis of spontaneous mutations at the aprt locus of hamster cells. Mol Cell Biol (1987) 1.26
Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res (1995) 1.26
Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors. Cancer Res (1991) 1.25
Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res (1996) 1.23
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets (2012) 1.21
Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem (1996) 1.20
Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene. DNA (1987) 1.20
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A (1998) 1.19
DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res (1993) 1.18
Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res (1994) 1.17
Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet (1993) 1.13
A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics (1999) 1.12
The p53 gene and its role in human brain tumors. Glia (1995) 1.11
Retinoblastoma and the progression of tumor genetics. Trends Genet (1988) 1.11
Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett (2001) 1.11
Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci U S A (2001) 1.11
Advances in the molecular genetics of gliomas. Curr Opin Oncol (1997) 1.10
Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2001) 1.10
Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer (1993) 1.10
The potential of TRAIL for cancer chemotherapy. Apoptosis (2001) 1.10
Tumor suppressors: recessive mutations that lead to cancer. Cell (1988) 1.09
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A (2000) 1.09
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg (2001) 1.09
Structure and sequence of mutations induced by ionizing radiation at selectable loci in Chinese hamster ovary cells. J Mol Biol (1986) 1.08
Detection of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma using the reverse transcriptase-polymerase chain reaction. Genes Chromosomes Cancer (1996) 1.08
Prediction of familial predisposition to retinoblastoma. N Engl J Med (1986) 1.08
Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (1997) 1.07
Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum Gene Ther (2000) 1.06
EGFR gene amplification--rearrangement in human glioblastomas. Int J Cancer (1995) 1.05
Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther (1996) 1.05
Recessive mutant genes predisposing to human cancer. Mutat Res (1986) 1.05
Rhabdomyosarcoma-associated locus and MYOD1 are syntenic but separate loci on the short arm of human chromosome 11. Proc Natl Acad Sci U S A (1990) 1.04
A defined region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res (1995) 1.04
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene (2000) 1.03
Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res (1993) 1.03
The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene (1999) 1.02
Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res (1999) 1.02
Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res (1995) 1.01
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene (1999) 1.01
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. J Biol Chem (2001) 1.00
Regulation of cholesterol biosynthesis in enucleated cells. J Biol Chem (1981) 1.00